Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:PTCT NASDAQ:RYTM NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$99.35-0.2%$97.89$47.89▼$114.99$6.06B0.5734,841 shs553,578 shsPTCTPTC Therapeutics$75.14+0.6%$70.54$43.17▼$87.50$6.23B0.561.09 million shs1.07 million shsRYTMRhythm Pharmaceuticals$88.38+0.8%$87.96$60.70▼$122.20$6.06B1.91517,566 shs554,263 shsZYMEZymeworks$22.88-0.4%$25.71$11.51▼$29.75$1.67B1.15702,575 shs522,957 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%+6.28%-10.81%+9.59%+105.01%PTCTPTC Therapeutics0.00%+5.88%+3.33%+16.51%+47.86%RYTMRhythm Pharmaceuticals0.00%+2.29%-5.61%+1.14%+36.30%ZYMEZymeworks0.00%-4.83%-4.51%0.00%+2,287,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$99.35-0.2%$97.89$47.89▼$114.99$6.06B0.5734,841 shs553,578 shsPTCTPTC Therapeutics$75.14+0.6%$70.54$43.17▼$87.50$6.23B0.561.09 million shs1.07 million shsRYTMRhythm Pharmaceuticals$88.38+0.8%$87.96$60.70▼$122.20$6.06B1.91517,566 shs554,263 shsZYMEZymeworks$22.88-0.4%$25.71$11.51▼$29.75$1.67B1.15702,575 shs522,957 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%+6.28%-10.81%+9.59%+105.01%PTCTPTC Therapeutics0.00%+5.88%+3.33%+16.51%+47.86%RYTMRhythm Pharmaceuticals0.00%+2.29%-5.61%+1.14%+36.30%ZYMEZymeworks0.00%-4.83%-4.51%0.00%+2,287,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 2.93Moderate Buy$138.3639.26% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3621.58% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$131.8149.14% UpsideZYMEZymeworks 2.82Moderate Buy$36.6760.26% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, PTCT, MIRM, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/9/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/3/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/3/2026ZYMEZymeworks HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.006/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/22/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.00(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$569.61M10.64$0.05 per share1,948.74$6.12 per share16.23PTCTPTC Therapeutics$1.73B3.60$8.78 per share8.56($2.56) per share-29.35RYTMRhythm Pharmaceuticals$217.17M27.89N/AN/A$2.08 per share42.49ZYMEZymeworks$81.26M20.56N/AN/A$3.59 per share6.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$23.36M-$13.61N/A431.96N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A35.613.46-22.58%-362.45%-6.76%8/6/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/AN/AN/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ZYME, PTCT, MIRM, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.282.091.99PTCTPTC TherapeuticsN/A2.442.36RYTMRhythm PharmaceuticalsN/A4.173.89ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/APTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals8.32%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals5.90%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AZYME, PTCT, MIRM, and RYTM HeadlinesRecent News About These CompaniesZymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 12 at 4:31 AM | americanbankingnews.comZymeworks (ZYME) Gets a Buy from Wells FargoJune 3, 2026 | theglobeandmail.comZymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC OptionalityMay 22, 2026 | seekingalpha.comVanguard Group Inc. Increases Position in Zymeworks Inc. $ZYMEMay 15, 2026 | marketbeat.comZymeworks Authorizes 2026 Share Repurchase Program, Affirms LiquidityMay 14, 2026 | tipranks.comZymeworks’ Earnings Call Balances Progress And PressureMay 14, 2026 | theglobeandmail.comZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | financialpost.comFZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)May 14, 2026 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | financialpost.comFZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZymeworks Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comHere's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comA Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return UpdatesMay 9, 2026 | finance.yahoo.comZymeworks Inc. (ZYME) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comZymeworks (ZYME) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comZymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comZymeworks Inc Registered Shs ZYMEMay 6, 2026 | morningstar.comMBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecificApril 30, 2026 | fiercebiotech.comFZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026April 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026ZYME, PTCT, MIRM, and RYTM Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$99.35 -0.19 (-0.19%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$99.37 +0.02 (+0.02%) As of 06/12/2026 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.PTC Therapeutics NASDAQ:PTCT$75.14 +0.43 (+0.58%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$75.14 0.00 (0.00%) As of 06/12/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$88.38 +0.72 (+0.82%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$89.97 +1.59 (+1.80%) As of 06/12/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Zymeworks NASDAQ:ZYME$22.88 -0.09 (-0.39%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$22.88 0.00 (-0.02%) As of 06/12/2026 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
